MNKD

SEC source: 0001193125-26-405736 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 713,258

F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

F2 · price: The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.20 and $3.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F1 · acquired: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

SEC source: 0001193125-26-391003 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 752,309

F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

F2 · price: The weighted average sales price of the reported transaction was $3.81 based on a range of prices between $3.76 and $3.87. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F1 · acquired: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

SEC source: 0001193125-26-343016 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 785,867

F2 · price: The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.86 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F1 · acquired: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

SEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 6

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 797,554

F4 · price: The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · acquired: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

SEC source: 0001193125-26-308129 · ownership.xml · nonDerivative · entry 5

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 824,918

F4 · price: The weighted average sales price of the reported transaction was $4.06 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · acquired: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

SEC source: 0001193125-26-308139 · ownership.xml · nonDerivative · entry 2

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,668

F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308139 · ownership.xml · nonDerivative · entry 1

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,343

F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

F2 · balance_after: Includes 1,991 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.

SEC source: 0001193125-26-308137 · ownership.xml · nonDerivative · entry 1

Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,398

F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

F2 · balance_after: Includes 2,775 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.

SEC source: 0001193125-26-308134 · ownership.xml · derivative · entry 6

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 93,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 5

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,058,142

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 4

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,070,473

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 3

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,082,045

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 2

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,090,298

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308134 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,123,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F2 · balance_after: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.

SEC source: 0001193125-26-308133 · ownership.xml · derivative · entry 6

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 350,260 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 5

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,433,779

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,492,683

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,556,679

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,604,160

F3 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308133 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,796,979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria.

F2 · balance_after: Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.

SEC source: 0001193125-26-308131 · ownership.xml · derivative · entry 7

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 93,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 5

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 821,663

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 4

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 838,041

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 3

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 855,795

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 2

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 868,457

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 1

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 920,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308132 · ownership.xml · derivative · entry 6

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 70,550 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 5

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 478,966

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 4

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 488,263

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 3

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 498,342

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 2

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 503,714

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308132 · ownership.xml · nonDerivative · entry 1

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 525,761

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 70,550 shares. The acquisition of 85,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 14,450 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308129 · ownership.xml · derivative · entry 6

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 93,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-308129 · ownership.xml · nonDerivative · entry 4

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 877,403

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308129 · ownership.xml · nonDerivative · entry 3

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 882,037

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308129 · ownership.xml · nonDerivative · entry 2

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 886,110

F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

SEC source: 0001193125-26-308129 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 901,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

SEC source: 0001193125-26-237456 · ownership.xml · derivative · entry 1

Friedman Michael A · CIK 0001298083 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F2 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F2 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237444 · ownership.xml · derivative · entry 3

Consiglio Ronald J · CIK 0001232088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,556

Underlying: Common Stock, $0.01 Par Value · 16,556 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F5 · derivative.exercise_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F5 · derivative.expiration_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237444 · ownership.xml · derivative · entry 2

Consiglio Ronald J · CIK 0001232088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F4 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F4 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F4 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237444 · ownership.xml · nonDerivative · entry 1

Consiglio Ronald J · CIK 0001232088 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,342

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 29, 2018. The purchase was approved by the Company's Board of Directors on May 20, 2026.

F2 · balance_after: 423,655 shares representing deferred restricted stock units were inadvertently included in Table I holdings on prior filings.

SEC source: 0001193125-26-237438 · ownership.xml · derivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F2 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F2 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237432 · ownership.xml · derivative · entry 2

Grancio Jennifer · CIK 0001807888 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F3 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237431 · ownership.xml · derivative · entry 2

HOOPER ANTHONY C · CIK 0001277244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,556

Underlying: Common Stock, $0.01 Par Value · 16,556 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F3 · derivative.exercise_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.expiration_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237431 · ownership.xml · derivative · entry 1

HOOPER ANTHONY C · CIK 0001277244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F2 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F2 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237430 · ownership.xml · derivative · entry 3

Shannon James Samuel · CIK 0001485417 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,556

Underlying: Common Stock, $0.01 Par Value · 16,556 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F4 · derivative.exercise_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F4 · derivative.expiration_date: Award granted in lieu of annual cash retainer payment for non-employee directors. Restricted stock unit shall vest immediately, but the shares shall not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237430 · ownership.xml · derivative · entry 2

Shannon James Samuel · CIK 0001485417 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F3 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-237429 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,026,122

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 29, 2018. The purchase was approved by the Company's Board of Directors on May 20, 2026.

SEC source: 0001193125-26-237428 · ownership.xml · nonDerivative · entry 1

Marasco Dominic · CIK 0002053897 · Pres, Endocrine Business Unit

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 344,246

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 29, 2018. The purchase was approved by the Company's Board of Directors on May 20, 2026.

F2 · balance_after: Includes 2,343 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025.

SEC source: 0001193125-26-237426 · ownership.xml · derivative · entry 2

MUNDKUR CHRISTINE · CIK 0001237264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F3 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.